Taiwan · Delayed Price · Currency is TWD CH Biotech R&D Statistics
Total Valuation
CH Biotech R&D has a market cap or net worth of TWD 9.39 billion. The enterprise value is 9.38 billion.
| Market Cap | 9.39B |
| Enterprise Value | 9.38B |
Important Dates
The next estimated earnings date is Tuesday, August 11, 2026.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | Mar 26, 2026 |
Share Statistics
CH Biotech R&D has 102.80 million shares outstanding.
| Current Share Class | 102.80M |
| Shares Outstanding | 102.80M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 24.95% |
| Owned by Institutions (%) | 0.03% |
| Float | 34.71M |
Valuation Ratios
The trailing PE ratio is 19.14.
| PE Ratio | 19.14 |
| Forward PE | n/a |
| PS Ratio | 5.11 |
| PB Ratio | 3.51 |
| P/TBV Ratio | 3.53 |
| P/FCF Ratio | 16.14 |
| P/OCF Ratio | 13.09 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.85, with an EV/FCF ratio of 16.13.
| EV / Earnings | 19.09 |
| EV / Sales | 5.11 |
| EV / EBITDA | 10.85 |
| EV / EBIT | 14.47 |
| EV / FCF | 16.13 |
Financial Position
The company has a current ratio of 1.08, with a Debt / Equity ratio of 0.23.
| Current Ratio | 1.08 |
| Quick Ratio | 0.93 |
| Debt / Equity | 0.23 |
| Debt / EBITDA | 0.72 |
| Debt / FCF | 1.08 |
| Interest Coverage | 39.80 |
Financial Efficiency
Return on equity (ROE) is 18.34% and return on invested capital (ROIC) is 19.24%.
| Return on Equity (ROE) | 18.34% |
| Return on Assets (ROA) | 9.94% |
| Return on Invested Capital (ROIC) | 19.24% |
| Return on Capital Employed (ROCE) | 23.15% |
| Weighted Average Cost of Capital (WACC) | 4.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.45 |
| Inventory Turnover | 2.49 |
Taxes
In the past 12 months, CH Biotech R&D has paid 111.03 million in taxes.
| Income Tax | 111.03M |
| Effective Tax Rate | 18.44% |
Stock Price Statistics
The stock price has increased by +17.35% in the last 52 weeks. The beta is 0.14, so CH Biotech R&D's price volatility has been lower than the market average.
| Beta (5Y) | 0.14 |
| 52-Week Price Change | +17.35% |
| 50-Day Moving Average | 94.95 |
| 200-Day Moving Average | 96.35 |
| Relative Strength Index (RSI) | 39.71 |
| Average Volume (20 Days) | 177,215 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CH Biotech R&D had revenue of TWD 1.84 billion and earned 491.30 million in profits. Earnings per share was 4.77.
| Revenue | 1.84B |
| Gross Profit | 1.54B |
| Operating Income | 650.94M |
| Pretax Income | 602.22M |
| Net Income | 491.30M |
| EBITDA | 838.18M |
| EBIT | 650.94M |
| Earnings Per Share (EPS) | 4.77 |
Balance Sheet
The company has 635.03 million in cash and 627.38 million in debt, with a net cash position of 7.66 million or 0.07 per share.
| Cash & Cash Equivalents | 635.03M |
| Total Debt | 627.38M |
| Net Cash | 7.66M |
| Net Cash Per Share | 0.07 |
| Equity (Book Value) | 2.68B |
| Book Value Per Share | 26.04 |
| Working Capital | 94.72M |
Cash Flow
In the last 12 months, operating cash flow was 716.77 million and capital expenditures -135.43 million, giving a free cash flow of 581.34 million.
| Operating Cash Flow | 716.77M |
| Capital Expenditures | -135.43M |
| Depreciation & Amortization | 187.73M |
| Net Borrowing | -164.74M |
| Free Cash Flow | 581.34M |
| FCF Per Share | 5.66 |
Margins
Gross margin is 83.68%, with operating and profit margins of 35.47% and 26.77%.
| Gross Margin | 83.68% |
| Operating Margin | 35.47% |
| Pretax Margin | 32.82% |
| Profit Margin | 26.77% |
| EBITDA Margin | 45.68% |
| EBIT Margin | 35.47% |
| FCF Margin | 31.68% |
Dividends & Yields
This stock pays an annual dividend of 4.80, which amounts to a dividend yield of 5.25%.
| Dividend Per Share | 4.80 |
| Dividend Yield | 5.25% |
| Dividend Growth (YoY) | 17.07% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 85.79% |
| Buyback Yield | n/a |
| Shareholder Yield | 5.25% |
| Earnings Yield | 5.23% |
| FCF Yield | 6.19% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 26, 2022. It was a forward split with a ratio of 1.15.
| Last Split Date | Jul 26, 2022 |
| Split Type | Forward |
| Split Ratio | 1.15 |
Scores
CH Biotech R&D has an Altman Z-Score of 5.32 and a Piotroski F-Score of 6.
| Altman Z-Score | 5.32 |
| Piotroski F-Score | 6 |